Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis

Trial Profile

Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Apr 2018

At a glance

  • Drugs Pevonedistat (Primary) ; Ruxolitinib (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Apr 2018 Planned End Date changed from 30 Apr 2021 to 31 Mar 2021.
    • 24 Apr 2018 Planned primary completion date changed from 30 Jun 2020 to 31 May 2020.
    • 24 Apr 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top